PubRank

Steven D Douglas

Author PubWeight™ 101.72‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol 2003 5.43
2 Depressive and anxiety disorders in women with HIV infection. Am J Psychiatry 2002 2.26
3 Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy. J Infect Dis 2004 1.98
4 Long-term observation of adolescents initiating HAART therapy: three-year follow-up. AIDS Res Hum Retroviruses 2007 1.84
5 Association of depression with viral load, CD8 T lymphocytes, and natural killer cells in women with HIV infection. Am J Psychiatry 2002 1.73
6 Vitamin D status in adolescents and young adults with HIV infection. Am J Clin Nutr 2006 1.49
7 Immune suppression and immune activation in depression. Brain Behav Immun 2010 1.48
8 Hepatitis C virus inhibits intracellular interferon alpha expression in human hepatic cell lines. Hepatology 2005 1.31
9 Real-time RT-PCR for quantitation of hepatitis C virus RNA. J Virol Methods 2002 1.29
10 Neurokinin 1 receptor isoforms and the control of innate immunity. Trends Immunol 2009 1.27
11 Morphine enhances hepatitis C virus (HCV) replicon expression. Am J Pathol 2003 1.25
12 Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescents. AIDS 2002 1.24
13 Substance P and neurokinin-1 receptor modulation of HIV. J Neuroimmunol 2004 1.24
14 Morphine enhances HIV infection of human blood mononuclear phagocytes through modulation of beta-chemokines and CCR5 receptor. J Investig Med 2002 1.23
15 Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy. AIDS Patient Care STDS 2008 1.22
16 Quantification of CCR5 mRNA in human lymphocytes and macrophages by real-time reverse transcriptase PCR assay. Clin Diagn Lab Immunol 2003 1.21
17 Natural killer cells inhibit hepatitis C virus expression. J Leukoc Biol 2004 1.21
18 CD8+CD38+ T cells but not HIV type 1 RNA viral load predict CD4+ T cell loss in a predominantly minority female HIV+ adolescent population. AIDS Res Hum Retroviruses 2004 1.19
19 HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers. AIDS 2006 1.15
20 Prevalence, diagnosis, and pharmacological treatment of mood disorders in HIV disease. Biol Psychiatry 2003 1.14
21 Differences in the length of the carboxyl terminus mediate functional properties of neurokinin-1 receptor. Proc Natl Acad Sci U S A 2008 1.14
22 Morphine enhances HIV infection of neonatal macrophages. Pediatr Res 2003 1.13
23 Immune reconstitution and predictors of virologic failure in adolescents infected through risk behaviors and initiating HAART: week 60 results from the PACTG 381 cohort. AIDS Res Hum Retroviruses 2006 1.11
24 Alcohol potentiates hepatitis C virus replicon expression. Hepatology 2003 1.11
25 Relationship of plasma HIV-1 RNA dynamics to baseline factors and virological responses to highly active antiretroviral therapy in adolescents (aged 12-22 years) infected through high-risk behavior. J Infect Dis 2004 1.11
26 Association of resolution of major depression with increased natural killer cell activity among HIV-seropositive women. Am J Psychiatry 2005 1.08
27 Glutathione, glutathione peroxidase, and selenium status in HIV-positive and HIV-negative adolescents and young adults. Am J Clin Nutr 2007 1.06
28 Alcohol potentiates HIV-1 infection of human blood mononuclear phagocytes. Alcohol Clin Exp Res 2002 1.06
29 Immune activation and oxidative damage in HIV-positive and HIV-negative adolescents. J Acquir Immune Defic Syndr 2005 1.06
30 Enhanced psychosocial well-being following participation in a mindfulness-based stress reduction program is associated with increased natural killer cell activity. J Altern Complement Med 2010 1.05
31 Methadone enhances human immunodeficiency virus infection of human immune cells. J Infect Dis 2001 1.04
32 Neurokinin-1 receptor antagonist (aprepitant) inhibits drug-resistant HIV-1 infection of macrophages in vitro. J Neuroimmune Pharmacol 2007 1.03
33 Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals. AIDS 2010 1.02
34 Substance P (SP) enhances CCL5-induced chemotaxis and intracellular signaling in human monocytes, which express the truncated neurokinin-1 receptor (NK1R). J Leukoc Biol 2008 1.01
35 HIV enhances substance P expression in human immune cells. FASEB J 2002 1.01
36 Depression and HIV infection: impact on immune function and disease progression. CNS Spectr 2003 1.01
37 A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults. PLoS One 2011 1.00
38 Selective serotonin reuptake inhibitor and substance P antagonist enhancement of natural killer cell innate immunity in human immunodeficiency virus/acquired immunodeficiency syndrome. Biol Psychiatry 2007 1.00
39 Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults. AIDS 2015 1.00
40 Association between alcohol use and HIV viral load. J Acquir Immune Defic Syndr 2011 0.99
41 Neurokinin-1 receptor antagonist (aprepitant) suppresses HIV-1 infection of microglia/macrophages. J Neuroimmune Pharmacol 2008 0.99
42 Peripheral blood lymphocyte subsets in adolescents: a longitudinal analysis from the REACH project. Clin Diagn Lab Immunol 2002 0.97
43 Real-time reverse transcription-PCR quantitation of substance P receptor (NK-1R) mRNA. Clin Diagn Lab Immunol 2005 0.97
44 Interleukin-1beta upregulates functional expression of neurokinin-1 receptor (NK-1R) via NF-kappaB in astrocytes. Glia 2004 0.97
45 Interleukin-1beta stimulates macrophage inflammatory protein-1alpha and -1beta expression in human neuronal cells (NT2-N). J Neurochem 2003 0.97
46 Quantification of substance p mRNA in human immune cells by real-time reverse transcriptase PCR assay. Clin Diagn Lab Immunol 2002 0.96
47 Naltrexone inhibits alcohol-mediated enhancement of HIV infection of T lymphocytes. J Leukoc Biol 2006 0.95
48 Alpha-defensins inhibit HIV infection of macrophages through upregulation of CC-chemokines. AIDS 2004 0.95
49 Neurokinin 1 receptor mediates membrane blebbing in HEK293 cells through a Rho/Rho-associated coiled-coil kinase-dependent mechanism. J Biol Chem 2009 0.95
50 Assessment of thymic activity in human immunodeficiency virus-negative and -positive adolescents by real-time PCR quantitation of T-cell receptor rearrangement excision circles. Clin Diagn Lab Immunol 2003 0.93
51 Perceived stress is associated with impaired T-cell response to HPV16 in women with cervical dysplasia. Ann Behav Med 2008 0.92
52 Neurokinin-1 receptor (NK1-R) expression in the brains of SIV-infected rhesus macaques: implications for substance P in NK1-R immune cell trafficking into the CNS. Am J Pathol 2010 0.92
53 Substance P induces rapid and transient membrane blebbing in U373MG cells in a p21-activated kinase-dependent manner. PLoS One 2011 0.91
54 Methylnaltrexone antagonizes opioid-mediated enhancement of HIV infection of human blood mononuclear phagocytes. J Pharmacol Exp Ther 2003 0.91
55 Substance P inhibits natural killer cell cytotoxicity through the neurokinin-1 receptor. J Leukoc Biol 2010 0.90
56 Substance P up-regulates macrophage inflammatory protein-1beta expression in human T lymphocytes. J Neuroimmunol 2002 0.90
57 Morphine withdrawal enhances hepatitis C virus replicon expression. Am J Pathol 2005 0.90
58 Detection of full-length and truncated neurokinin-1 receptor mRNA expression in human brain regions. J Neurosci Methods 2007 0.89
59 Human neuronal cells (NT2-N) express functional substance P and neurokinin-1 receptor coupled to MIP-1 beta expression. J Neurosci Res 2003 0.89
60 Central and peripheral markers of neurodegeneration and monocyte activation in HIV-associated neurocognitive disorders. J Neurovirol 2015 0.89
61 Association of depression, CD8+ T lymphocytes, and natural killer cell activity: implications for morbidity and mortality in Human immunodeficiency virus disease. Curr Psychiatry Rep 2003 0.88
62 Interleukin-1beta induces macrophage inflammatory protein-1beta expression in human hepatocytes. Cell Immunol 2003 0.88
63 Cytokine and chemokine gene polymorphisms among ethnically diverse North Americans with HIV-1 infection. J Acquir Immune Defic Syndr 2004 0.88
64 A non-peptide substance P antagonist down-regulates SP mRNA expression in human mononuclear phagocytes. J Neuroimmunol 2002 0.88
65 CD8+ T cell depletion amplifies hepatitis C virus replication in peripheral blood mononuclear cells. J Infect Dis 2005 0.87
66 Morphine inhibits CD8+ T cell-mediated, noncytolytic, anti-HIV activity in latently infected immune cells. J Leukoc Biol 2005 0.87
67 Vitamins C and E in adolescents and young adults with HIV infection. Am J Clin Nutr 2006 0.87
68 Innate immune markers in mothers and fathers of children newly diagnosed with cancer. Neuroimmunomodulation 2008 0.87
69 CD4+ and CD8+ T cell receptor repertoire perturbations with normal levels of T cell receptor excision circles in HIV-infected, therapy-naive adolescents. AIDS Res Hum Retroviruses 2003 0.86
70 Down syndrome: immunologic and epidemiologic associations-enigmas remain. J Pediatr 2005 0.85
71 Longitudinal analysis of lymphocyte ratios and HIV-1 intracellular DNA levels in children. J Infect Dis 2004 0.85
72 Increased proliferation within T lymphocyte subsets of HIV-infected adolescents. AIDS Res Hum Retroviruses 2002 0.84
73 Selective serotonin reuptake inhibitor suppression of HIV infectivity and replication. Psychosom Med 2010 0.84
74 Programmed death 1 receptor changes ex vivo in HIV-infected adults following initiation of highly active antiretroviral therapy. Clin Vaccine Immunol 2012 0.83
75 Substance P and Human Immunodeficiency Virus Infection: Psychoneuroimmunology. CNS Spectr 2002 0.82
76 A sensitive and rapid liquid chromatography-tandem mass spectrometry method for the quantification of the novel neurokinin-1 receptor antagonist aprepitant in rhesus macaque plasma, and cerebral spinal fluid, and human plasma with application in translational NeuroAIDs research. J Pharm Biomed Anal 2008 0.82
77 Neurokinin 1 receptor mediates membrane blebbing and sheer stress-induced microparticle formation in HEK293 cells. PLoS One 2012 0.82
78 Nested RT-PCR. Sensitivity controls are essential to determine the biological significance of detected mRNA. Methods Mol Biol 2002 0.82
79 Planning Future Strategies for Domestic and International NeuroAIDS Research, July 24-25, 2008. J Neuroimmune Pharmacol 2009 0.82
80 Morphine upregulates functional expression of neurokinin-1 receptor in neurons. J Neurosci Res 2006 0.81
81 Novel method for determination of substance P levels in unextracted human plasma by using acidification. Clin Vaccine Immunol 2009 0.81
82 CCR2 and CCR5 genotypes in HIV type 1-infected adolescents: limited contributions to variability in plasma HIV type 1 RNA concentration in the absence of antiretroviral therapy. AIDS Res Hum Retroviruses 2002 0.81
83 An in vitro model of morphine withdrawal manifests the enhancing effect on human immunodeficiency virus infection of human T lymphocytes through the induction of substance P. Am J Pathol 2006 0.80
84 Elevated plasma substance P in sickle cell disease and vaso-occlusive crisis. Med Hypotheses 2008 0.80
85 Natural killer cell inhibits human immunodeficiency virus replication in chronically infected immune cells. Antiviral Res 2006 0.79
86 Substance P-neurokinin-1 receptor interaction upregulates monocyte tissue factor. J Neuroimmunol 2011 0.79
87 Efavirenz liquid formulation in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2002 0.79
88 Phase I/II trial of intravenous recombinant interleukin-2 in HIV-infected children. AIDS 2003 0.78
89 Measurement of plasma-derived substance P: biological, methodological, and statistical considerations. Clin Vaccine Immunol 2006 0.78
90 Substance P enhances HIV-1 infection in human fetal brain cell cultures expressing full-length neurokinin-1 receptor. J Neurovirol 2013 0.78
91 A non-peptide substance P antagonist (CP-96,345) inhibits morphine-induced NF-kappa B promoter activation in human NT2-N neurons. J Neurosci Res 2004 0.78
92 Mimic-based RT-PCR quantitation of substance P mRNA in human mononuclear phagocytes and lymphocytes. Methods Mol Biol 2002 0.77
93 Expression of substance P, neurokinin-1 receptor and immune markers in the brains of individuals with HIV-associated neuropathology. J Neurol Sci 2013 0.77
94 Analog of somatostatin vapreotide exhibits biological effects in vitro via interaction with neurokinin-1 receptor. Neuroimmunomodulation 2013 0.76
95 Plasma cytokines and oxidative damage in HIV-positive and HIV-negative adolescents and young adults: a protective role for IL-10? Free Radic Res 2005 0.76
96 The effects of avoidance on cytotoxic/suppressor T cells in women with cervical lesions. Psychooncology 2003 0.76
97 Alcohol suppresses IL-2-induced CC chemokine production by natural killer cells. Alcohol Clin Exp Res 2005 0.76
98 Neuropsychopharmacologic treatment of depression and other neuropsychiatric disorders in HIV-infected individuals. CNS Spectr 2003 0.76
99 CCR5 expression and beta-chemokine production during placental neonatal monocyte differentiation. Pediatr Res 2003 0.75
100 The glucocorticoid antagonist RU-486 suppresses HIV infectivity and replication. J Neuropsychiatry Clin Neurosci 2013 0.75
101 PET measurement of receptor occupancy as a tool to guide dose selection in neuropharmacology: are we asking the right questions? J Clin Psychopharmacol 2013 0.75